Phase I-II Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Combination With Topotecan in Patients With Chemosensitive Recurrent Small Cell Lung Cancer (SCLC)
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 2
- 试验地点
- 1
- 主要终点
- Maximum tolerated dose of the combination as the recommended dose for phase II trial [Phase I]; objective response rate of the combination [Phase II]; toxicity and safety profile of the combination [Phase II]
研究概览
简要总结
The purpose of this study is to evaluate the maximum tolerated dose, the activity and the safety profile of the combination of vorinostat and topotecan in patients with recurrent small cell lung cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven diagnosis of SCLC;
- •Limited or extensive-stage disease in patients who have received a single chemotherapy regimen or combined modality (chemotherapy + chest radiotherapy) regimen and relapsed after completion of first-line chemotherapy (sensitive relapse);
- •Age >/= 18 years;
- •ECOG Performance Status 0-2;
- •Life expectancy of at least 12 weeks;
- •Measurable lesions according to RECIST criteria;
- •Adequate cardiac, hepatic, renal, and bone marrow function;
- •Written informed consent.
排除标准
- •Prior treatment with an HDAC inhibitor;
- •Symptomatic and/or unstable pre-existing brain metastases;
- •Superior Vena Cava Syndrome;
- •Spinal cord compression;
- •Severe or uncontrolled medical diseases (Hypertension, diabetes, congestive heart failure, myocardial infarction within 6 months of study, chronic renal disease, or active uncontrolled infections);
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ;
- •Pregnant or breastfeeding women.
研究组 & 干预措施
Vorinostat/Topotecan
Vorinostat/topotecan dose escalation regimen. vorinostat is administered orally once a day for 7 to 14 consecutive days, according to the dose level.Topotecan is administered I.V. for 5 consecutive days every three weeks.
Vorinostat dose levels go from 300 mg/day for 7 days to 400 mg/day for 14 days. Topotecan dose levels go from 1,2 mg/m2 to 1,5 mg/m2
干预措施: topotecan, vorinostat (Drug)
结局指标
主要结局
Maximum tolerated dose of the combination as the recommended dose for phase II trial [Phase I]; objective response rate of the combination [Phase II]; toxicity and safety profile of the combination [Phase II]
时间窗: Limiting tolerated dose (Phase I); efficacy/toxicity after the inclusion of the last patient (Phase II)
次要结局
- To assess the antitumor activity of the combination in terms of time to progression (TTP) and overall survival (OS) [Phase II](After the follow up period)
研究者
Armando Santoro, MD
MD
Istituto Clinico Humanitas